Chirayu Polyclinic
C h i r a y u P o l y c l i n i c
Targeted Therapy in Lung Cancer

Targeted Therapy in Lung Cancer

Table of Contents

📌 Click to View

Introduction

Targeted Therapy in Lung Cancer focuses on attacking specific genetic changes that drive tumor growth. Unlike traditional chemotherapy, which affects many healthy cells as well, targeted therapy aims directly at cancer-specific pathways. As a result, patients often tolerate the treatment better and experience more precise disease control. At
Chirayu Polyclinic, our oncology team reviews each patient’s condition and recommends the most suitable targeted options.

 

What is Targeted Therapy?

Targeted therapy uses specialized medications—such as small-molecule inhibitors and monoclonal antibodies—to block cancer-specific mutations. These drugs work on biomarkers like EGFR, ALK, ROS1, BRAF, and PD-L1. Doctors identify these markers through molecular testing of tissue samples or blood (liquid biopsy). Once the report becomes available, the oncology team matches the drug to the mutation.

 

How Targeted Therapy Works

After completing a biopsy and molecular analysis, oncologists choose medicines that stop faulty proteins or block signals that help cancer cells survive. Some drugs directly inhibit abnormal proteins, while others prevent tumors from building new blood vessels. Additionally, immune-targeted agents help the immune system recognize and destroy cancer cells more effectively. Consequently, patients often notice faster symptom relief.

 

Benefits & Limitations

  • Benefits: Targeted therapy offers precise action, faster response, and generally fewer whole-body side effects than standard chemotherapy. Moreover, many patients see quick tumor shrinkage.
  • Limitations: Treatment works only when the tumor carries a targetable mutation. Over time, cancer may also develop resistance, and some patients face challenges with cost or drug availability.

 

Who Is a Candidate?

Most patients with non-small cell lung cancer (NSCLC) undergo molecular profiling. If the tests reveal actionable mutations such as EGFR, ALK, ROS1, NTRK, or BRAF, oncologists may recommend targeted therapy. Furthermore, a multidisciplinary discussion ensures that every patient receives an individualized treatment plan.
Learn more.

 

Treatment Process & Side Effects

Once the team confirms the mutation, treatment usually begins quickly. Patients receive targeted drugs either orally or through IV infusion, mostly in outpatient settings for convenience. Side effects differ by medication type. However, common issues include mild skin rash, diarrhea, fatigue, changes in liver enzymes, or fluctuations in blood pressure. Therefore, doctors schedule regular blood tests and imaging to monitor progress.

 

Outlook & Follow-up

Many patients achieve long-term disease control or meaningful remission with targeted therapy. Still, resistance mutations may eventually appear. When that happens, oncologists shift to next-line targeted drugs or combination treatments. Follow-up visits typically include clinical evaluation, CT or PET imaging, and, when needed, repeat molecular testing. Overall, continuous monitoring helps maintain the best possible outcome.

 

FAQ

What is targeted therapy for lung cancer?

Targeted therapy uses drugs that block specific genetic changes that drive cancer growth. Doctors rely on molecular testing to choose the right treatment.

How do doctors test patients for targeted therapy?

Doctors perform a tissue biopsy or a liquid biopsy and run advanced molecular panels (NGS). These tests reveal mutations that guide therapy decisions.

Is targeted therapy better than chemotherapy?

Targeted drugs often provide better results with fewer side effects when the tumor carries an actionable mutation. Even so, chemotherapy still plays a vital role and may complement targeted therapy when needed.

 

Resources & Further Reading

Explore trusted sources for more information:

NCI: Targeted Cancer Therapies
ASCO: Cancer Care Guidelines

Leave a Reply

Your email address will not be published. Required fields are marked *